Endocrine Board Review 6th Edition (2014)
Endocrine Board Review 6th Edition (2014)
EBR 2014 in print provides a consolidated review for preparing for certification and recertification. This printed book is comprised of 238 mock exam questions based on the ABIM blueprint for certification and is an excellent study tool for endocrine fellows preparing for initial certification, practicing physicians preparing to re-certify, or anyone seeking an intensive knowledge assessment.
TO CLAIM CME
- This form is for the Endocrine Board Review 6th Edition book
- To evaluate this activity and claim CME, click "Take Course" to the right
This continuing medical education activity should be of substantial interest to endocrinologists, internists, and endocrine fellows preparing for the board examination or recertification; or endocrinologists and other healthcare practitioners seeking a review in endocrinology.
Upon completion of this educational activity, learners will be able to demonstrate enhanced medical knowledge and clinical skills across all major areas of endocrinology; apply knowledge and skills in diagnosing, managing, and treating a wide spectrum of endocrine disorders; and successfully complete the board examination for certification or recertification in the subspecialty of endocrinology, diabetes, and metabolism.
Bradley D. Anawalt, MD; University of Washington
Daniel H. Bessesen, MD; University of Colorado School of Medicine
Henry B. Burch, MD; Walter Reed National Military Medical Center
David A. D’Alessio, MD; University of Cincinnati
James W. Findling, MD; Medical College of Wisconsin
Ira J. Goldberg, MD; Columbia University
Jennifer B. Marks, MD; University of Miami
Mark E. Molitch, MD; Northwestern University Feinberg School of Medicine
Nelson Watts, MD; Mercy Health
Margaret E. Wierman, MD; University of Colorado School of Medicine
The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships:
Daniel H Bessesen, MD: DSMB Member, Enteromedics
David A D’Alessio, MD: Consultant, Janssen, Lilly, Novo Nordisk, and Roche; Speaker, Merck
James W Findling, MD: Consultant, Corcept; Investigator, Novartis
Ira J Goldberg, MD: Consultant, AstraZeneca, ISIS, Novartis, and Janssen; Consultant and Speaker, Merck
Jennifer B Marks, MD: Investigator, Amylin, Bristol-Myers Squibb, Eli Lilly & Co, Sanofi
Mark E Molitch, MD: Consultant, Chiasma/Genentech, Lilly; Consultant and Research Grant Support, Corcept, Ipsen, Novartis, Novo Nordisk
Nelson Watts, MD: Co-founder, stockholder, and director, OsteoDynamics; Consultant, AbbVie, Amarin, Bristol-Myers Squibb, Corcept, Endo, Imagepace, Janssen, Lilly, Noven, Novo Nordisk, Pfizer/Wyeth, Quark, Radius, Sanofi; Speaker, Warner Chilcott; Consultant and Speaker, Amgen, Merck, Novartis; Health System receives research grant support, Merck, NPS
Margaret Wierman, MD: Advisory Board Member, Genentech, Ipsen; Advisory Board Member and Investigator, Pfizer; Investigator, Novartis, Prolor.
The following faculty reported no relevant financial relationships: Bradley D Anawalt, MD; Henry B Burch, MD; and Ann Danoff, MD.
The following CEU Steering Committee members who planned and/or reviewed content for this activity reported relevant financial relationships:
Maria Fleseriu, MD: Research Support, Corcept, Ipsen, Novartis; Advisory Board, Genentech, Ipsen, Novartis
Whitney Goldner, MD; Research Support, Eisai, Astra Zeneca; Speaker, Genzyme
Susan A Sherman, MD: Stock, BMS, HCA, ARCA Pharma; Spouse: Speaker, AstraZeneca
Jennifer Sipos, MD: Speaker, Veracyte, Genzyme
Hirotaka Shibata, MD, PhD: Grant Support, Ono Pharma, Takeda, Tanabe-Mitsubishi; Speaker, Dainihou-Sumitous, Asteras; Grant Support and Speaker, Pfizer, Inc., MSD
Robert C Smallridge, MD: Principal Investigator, Novo Nordisk
The following CEU Steering Committee members who planned and/or reviewed content for this activity reported no relevant financial relationships: Carlos A Aguilar Salinas, MD; Carolyn B Becker, MD; Richard S Bockman, MD; Ann Danoff, MD; Sabrina Gill, MD, MPH; Ariel Sánchez, MD, PhD; Nalini Shah, DM.
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
- 20.00 AMA PRA Category 1 Credits™
- 20.00 CME Certificate of Participation